Intellect Neurosciences appeals European patent decision

15 December 2011

US neuro drug discovery firm Intellect Neurosciences (OTCBB: ILNS) says that it has filed an appeal regarding a preliminary decision of the European Patent Office (EPO) to revoke the company's ANTISENILIN monoclonal antibody platform patents.

Intellect Neurosciences has granted a royalty bearing license to Wyeth and Elan Pharma International regarding patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease, including Bapineuzumab.

The preliminary decision of the EPO resulted from a challenge by major pharmaceutical companies that are co-developing bapineuzumab, which is in Phase III clinical trials for Alzheimer's disease. Intellect has ANTISENILIN patents pending in the USA and has been granted patents in Japan, China and several other countries. None of the patents granted outside Europe were challenged.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK